Projected life-year gains with semaglutide in individuals with cardiovascular disease without type 2 diabetes in the UK.
Level 3 - non-randomized controlled study
Retrospective cohort study applying external trial effect estimates to electronic health record data via actuarial modeling
PubMed 41800807 · doi:10.1530/EC-25-0903
What was done
Researchers identified 19,117 individuals aged ≥45 years with established cardiovascular disease, BMI ≥27 kg/m², and no type 2 diabetes from the Discover linked electronic health record database in North West London (cohort entry 2004–2019). Trial effect estimates from the SELECT trial were applied to baseline cohort risks using actuarial life tables (Arriaga method for overall life expectancy and Sullivan method for cardiovascular event-free life expectancy).
What was found
In the cohort (63% men, mean age 65.4 years), projected semaglutide treatment yielded an estimated average gain in overall life expectancy of 1.9 years. Semaglutide was predicted to increase cardiovascular event-free life expectancy by 2.0 years. Gains occurred across all age groups but were higher in younger age groups (sub-age numerical values were not reported in the abstract).
Why it matters
This study translates relative risk reductions from a major trial into absolute projected longevity metrics, illustrating the potential lifetime population health gains of semaglutide for secondary cardiovascular prevention in patients without diabetes.
Limits
Findings represent mathematical projections rather than directly observed survival outcomes in treated patients. The model assumes sustained treatment adherence and persistent relative risk reduction over a lifetime matching trial conditions. The abstract reports no confidence intervals, specific sub-group numbers, or safety outcomes, and data are derived from a single UK region.
Cited by
- partial GLP-1 receptor agonists add approximately 5 to 10 years to the lifespan of people who are obese or have chronic conditions.